KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Diluted Average) (2018 - 2025)

Esperion Therapeutics' Shares Outstanding (Diluted Average) history spans 8 years, with the latest figure at $207.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 11.05% year-over-year to $207.9 million; the TTM value through Dec 2025 reached $207.9 million, up 11.05%, while the annual FY2025 figure was $207.9 million, 11.05% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $207.9 million in Q4 2025 per ESPR's latest filing, up from $200.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $207.9 million in Q4 2025 to a low of $26.0 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $116.5 million, with a median of $106.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): dropped 9.11% in 2021, then soared 156.31% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $28.9 million in 2021, then surged by 129.76% to $66.4 million in 2022, then skyrocketed by 55.26% to $103.1 million in 2023, then soared by 81.54% to $187.2 million in 2024, then grew by 11.05% to $207.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Shares Outstanding (Diluted Average) are $207.9 million (Q4 2025), $200.7 million (Q3 2025), and $197.5 million (Q2 2025).